Researchers at the Strelitz Diabetes Center are seeking a variety of participants for our current research studies. People with Diabetes Mellitus type 1 or 2, Diabetic Peripheral Neuropathy, Chronic Kidney Disease, and/or uncontrolled high blood pressure may be great candidates for our clinical studies. Some of these studies are testing new treatments while others are developing a deeper understanding of the disease mechanisms.
We are also seeking people who are interested in our community-based lifestyle studies, as well as an early cancer detection study. Please, see below for more extensive information surrounding our current projects!
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction with Macupatide and Eloralintide, Alone or in Combination, in Adult Participants with Obesity or Overweight and with Type 2 Diabetes
Primary Investigator: Dr. Elias Siraj, MD
Sponsor: Lilly
Summary: The purpose of this study is to assess the efficacy and safety of macupatide and eloralintide alone or in combination for weight reduction in participants with obesity or overweight and with type 2 diabetes (T2D).
Point of contact:
- Taneisha Sears, MPH | SearstTL@odu.edu | 757-446-5285
Start date: Currently recruiting participants.
Eligibility: You may be eligible to participate in this study if you:
- Age 18–75 years
- Diagnosis of Type 2 Diabetes for > 6 months
- A1C between 7.5 and 10.5
- Treated for at least 3 months with any of the following 3 options only (alone or in any combination): diet and exercise, metformin, SGLT-2 inhibitor .
- BMI ≥ 27
FORWARD2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to
Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
Primary Investigator: David Lieb, MD
Sponsor: Immunovant
Summary: The purpose of this study is to demonstrate that IMVT-1402 is an effective treatment for GD as assessed by the proportion of IMVT-1402– treated participants who are euthyroid at Week 26 without the need for concomitant antithyroid drug (ATD) therapy compared to placebo.
Point of contact:
- Taneisha Sears, MPH | SearstTL@odu.edu | 757-446-5285
Start date: Currently recruiting participants.
Eligibility: You may be eligible to participate in this study if you:
∙ Age 18–75 years
∙ Prior diagnosis of Graves’ Disease
∙ Currently or previously treated with antithyroid drugs (ATDs) for ≥ 3 months
FINALITY-HF: A randomized, double-blind, placebo-controlled pragmatic study to evaluate Finerenone on clinical efficacy and safety in patients with Heart Failure and reduced ejection fraction who are intolerant of or not eligible for treatment with steroidal mineralocorticoid receptor antagonists
Primary Investigator: Dr. Elias Siraj, MD
Sponsor: CPC Clinical Research
Summary: The purpose of this study is to evaluate the efficacy and safety of finerenone in participants with HFrEF who are intolerant of or not eligible for treatment with sMRA.
Point of contact:
- Taneisha Sears, MPH | SearstTL@odu.edu | 757-446-5285
Start date: Currently recruiting participants.
Eligibility: You may be eligible to participate in this study if you:
- Male or female, 18 years of age or older
- Diagnosed with symptomatic HFrEF
- Not currently on sMRA therapy
Clinical and Translational Outcomes of a Tailored Exercise Intervention in Obese African-American Women with Type 2 Diabetes
Primary Investigator: Henri Parson, PhD
Sponsor: VHS-NSU
Summary: The purpose of this study is to assess the impact of a 24-week tiered, supervised, and culturally sensitive physical activity intervention in obese AA women with type 2 diabetes. Cardiovascular fitness and biomarkers of cardiometabolic health in obese AA women with type 2 diabetes will also be assessed.
Point of contact:
- Jankiben Patel, MPH | Patelj1@odu.edu | 757-446-0577
Start date: Currently recruiting participants.
Eligibility: You may be eligible to participate in this study if you:
- African-American – self identified females
- Body mass index (BMI) ≥30 and ≤48 kg/m2
- Ages 18 – 70 with a diagnosis of type 2 diabetes mellitus without use of insulin or other excluded medications. Diet controlled diabetes is acceptable.
- HbA1c at screening level of 7 % to 10%
- Stable use of antidiabetic agents for 6 weeks or more and remains unchanged during the study intervention.
- Sedentary lifestyle- Self- reporting 60 min/ week or less of moderate to vigorous PA for the past 3 months.